ArticleInternational journal of urology : official journal of the Japanese Urological Association2026
Mixed Response to Nivolumab Among Different Metastatic Sites in Patients With Metastatic Renal Cell Carcinoma: Incidence and Clinical Implications.
Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDiscordant responses to immune checkpoint inhibition (ICIs) may occur at different sites in metastatic renal cell carcinoma (mRCC). This study investigated the incidence and prognostic significance of mixed response in mRCC patients treated with nivolumab.
methodsWe retrospectively analyzed 116 mRCC patients who underwent nivolumab monotherapy without prior ICIs. The best overall response (BOR) was evaluated for each patient using RECIST version 1.1, and organ-specific responses were assessed for each metastatic site. Patients were classified into three groups: responders (lesion shrinkage in one or more metastatic organs without growth in any organ), non-responders (no lesion shrinkage in any organ), and mixed responders (co-existence of metastatic organ with shrinking lesions and those with growing lesions).
resultsThe median age was 68 years, and 74.1% of patients were male. The IMDC risk was favorable/intermediate/poor in 17/79/20 patients, respectively. BOR was CR/PR/SD/PD in 2/24/38/52 patients, respectively; objective response rate (ORR) was 22.4%. In organ-specific responses, ORR was lower for bone (7.1%), kidney (8.8%), and brain (0%) metastases than for other sites (17.4%-50.0%). The analysis classified 49 (42.2%), 15 (12.9%), and 52 (44.8%) patients as responders, mixed responders, and non-responders, respectively. During a median follow-up of 20.9 months, the median overall survival (OS) was 45.7 months. Two-year OS rate was 72.7% overall, and 92.2%, 90.0%, and 46.4% for responders, mixed responders, and non-responders, respectively (p < 0.001).
conclusionsNivolumab yielded diverse organ-specific responses, with 12.9% of patients exhibiting mixed response. Further studies are required to explore optimal management of mixed responders to immune checkpoint inhibition in mRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.